Accessibility Menu
G1 Therapeutics logo

G1 Therapeutics

(NASDAQ) GTHX

Current PriceN/A
Market CapN/A
Since IPO (2017)-52%
5 Year-80%
1 Year+380%
1 Month+1%

G1 Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$58.20M

Net Income (TTM)

$44.77M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

GTHX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About G1 Therapeutics

Industry

Biotechnology

Employees

100

CEO

Jack Bailey, Jr., MBA

Headquarters

Research Triangle Park, NC 27709, US

GTHX Financials

Key Financial Metrics (TTM)

Gross Margin

91%

Operating Margin

-48%

Net Income Margin

-58%

Return on Equity

-92%

Return on Capital

-43%

Return on Assets

-39%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Short Interest

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$75.32M

Operating Income

$39.53M

EBITDA

$34.30M

Operating Cash Flow

$38.34M

Capital Expenditure

$0.00

Free Cash Flow

$38.34M

Cash & ST Invst.

$82.22M

Total Debt

$57.17M

G1 Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$16.55M

-61.0%

Gross Profit

$15.81M

-61.4%

Gross Margin

95.57%

N/A

Market Cap

N/A

N/A

Market Cap/Employee

N/A

N/A

Employees

100

N/A

Net Income

$5.47M

-162.8%

EBITDA

$2.62M

-120.4%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Net Cash

$12.83M

-73.4%

Accounts Receivable

$13.31M

+1.0%

Inventory

$13.38M

-14.2%

Long Term Debt

$36.55M

-34.6%

Short Term Debt

$11.41M

N/A

Return on Assets

-39.47%

N/A

Return on Invested Capital

-43.05%

N/A

Free Cash Flow

$5.27M

-137.4%

Operating Cash Flow

$5.27M

-137.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VIGLVigil Neuroscience, Inc.
$8.05+0.00%
ORTXOrchard Therapeutics plc
$16.70+0.30%
RVNCRevance Therapeutics, Inc.
$3.65+0.00%
CKPTCheckpoint Therapeutics, Inc.
$4.26+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$45.69-0.01%
VGVenture Global
$14.29-0.04%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.35+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.97-0.06%

Questions About GTHX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.